Literature DB >> 24867099

Release modeling and comparison of nanoarchaeosomal, nanoliposomal and pegylated nanoliposomal carriers for paclitaxel.

Fatemeh Movahedi1, Hasan Ebrahimi Shahmabadi, Seyed Ebrahim Alavi, Maedeh Koohi Moftakhari Esfahani.   

Abstract

Breast cancer is the most prevalent cancer among women. Recently, delivering by nanocarriers has resulted in a remarkable evolution in treatment of numerous cancers. Lipid nanocarriers are important ones while liposomes and archaeosomes are common lipid nanocarriers. In this work, paclitaxel was used and characterized in nanoliposomal and nanoarchaeosomal form to improve efficiency. To increase stability, efficiency and solubility, polyethylene glycol 2000 (PEG 2000) was added to some samples. MTT assay confirmed effectiveness of nanocarriers on MCF-7 cell line and size measuring validated nano-scale of particles. Nanoarchaeosomal carriers demonstrated highest encapsulation efficiency and lowest release rate. On the other hand, pegylated nanoliposomal carrier showed higher loading efficiency and less release compared with nanoliposomal carrier which verifies effect of PEG on improvement of stability and efficiency. Additionally, release pattern was modeled using artificial neural network (ANN) and genetic algorithm (GA). Using ANN modeling for release prediction, resulted in R values of 0.976, 0.989 and 0.999 for nanoliposomal, pegylated nanoliposomal and nanoarchaeosomal paclitaxel and GA modeling led to values of 0.954, 0.951 and 0.976, respectively. ANN modeling was more successful in predicting release compared with the GA strategy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24867099     DOI: 10.1007/s13277-014-2125-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  11 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

Review 2.  Structures of archaebacterial membrane lipids.

Authors:  G D Sprott
Journal:  J Bioenerg Biomembr       Date:  1992-12       Impact factor: 2.945

3.  Artificial neural networks: comparison of two programs for modeling a process of nanoparticle preparation.

Authors:  Névine Rizkalla; Patrice Hildgen
Journal:  Drug Dev Ind Pharm       Date:  2005-12       Impact factor: 3.225

Review 4.  Delivery of peptide and protein drugs over the blood-brain barrier.

Authors:  Ivona Brasnjevic; Harry W M Steinbusch; Christoph Schmitz; Pilar Martinez-Martinez
Journal:  Prog Neurobiol       Date:  2009-01-24       Impact factor: 11.685

Review 5.  A node between proliferation, apoptosis, and growth arrest.

Authors:  M V Blagosklonny
Journal:  Bioessays       Date:  1999-08       Impact factor: 4.345

6.  Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.

Authors:  J Allen Zhang; Gopal Anyarambhatla; Lan Ma; Sydney Ugwu; Tong Xuan; Tommaso Sardone; Imran Ahmad
Journal:  Eur J Pharm Biopharm       Date:  2005-01       Impact factor: 5.571

Review 7.  Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?

Authors:  Jianfeng Guo; Ludovic Bourre; Declan M Soden; Gerald C O'Sullivan; Caitriona O'Driscoll
Journal:  Biotechnol Adv       Date:  2011-03-22       Impact factor: 14.227

8.  Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.

Authors:  Tao Yang; Fu-De Cui; Min-Koo Choi; Jei-Won Cho; Suk-Jae Chung; Chang-Koo Shim; Dae-Duk Kim
Journal:  Int J Pharm       Date:  2007-02-13       Impact factor: 5.875

Review 9.  Nanoparticle delivery systems in cancer vaccines.

Authors:  Yogita Krishnamachari; Sean M Geary; Caitlin D Lemke; Aliasger K Salem
Journal:  Pharm Res       Date:  2010-08-19       Impact factor: 4.580

10.  Current operative management of breast cancer: an age of smaller resections and bigger cures.

Authors:  Jack W Rostas; Donna Lynn Dyess
Journal:  Int J Breast Cancer       Date:  2011-12-18
View more
  5 in total

1.  In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin.

Authors:  Maryam Sadat Ashrafzadeh; Azim Akbarzadeh; Amir Heydarinasab; Mehdi Ardjmand
Journal:  Int J Nanomedicine       Date:  2020-09-23

2.  Enhancing the efficacy of albendazole for liver cancer treatment using mesoporous silica nanoparticles: an in vitro study.

Authors:  Mohsen Ghaferi; Warda Zahra; Azim Akbarzadeh; Hasan Ebrahimi Shahmabadi; Seyed Ebrahim Alavi
Journal:  EXCLI J       Date:  2022-01-11       Impact factor: 4.068

Review 3.  Application of Mesoporous Silica Nanoparticles in Cancer Therapy and Delivery of Repurposed Anthelmintics for Cancer Therapy.

Authors:  Maedeh Koohi Moftakhari Esfahani; Seyed Ebrahim Alavi; Peter J Cabot; Nazrul Islam; Emad L Izake
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

4.  A PEGylated Nanostructured Lipid Carrier for Enhanced Oral Delivery of Antibiotics.

Authors:  Seyed Ebrahim Alavi; Urooj Bakht; Maedeh Koohi Moftakhari Esfahani; Hossein Adelnia; Seyed Hossein Abdollahi; Hasan Ebrahimi Shahmabadi; Aun Raza
Journal:  Pharmaceutics       Date:  2022-08-11       Impact factor: 6.525

5.  Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation.

Authors:  Mohsen Ghaferi; Mohammad Javad Asadollahzadeh; Azim Akbarzadeh; Hasan Ebrahimi Shahmabadi; Seyed Ebrahim Alavi
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.